Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Rui Filipe Libânio Osório Marta. (2019) Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metabolism Reviews 51:3, pages 378-387.
Read now
Read now
David E. Smith. (2019) The Role of the Journal of Psychedelic Drugs in the Evolution of Psychedelic Medicine. Journal of Psychoactive Drugs 51:2, pages 98-101.
Read now
Read now
Albert Garcia-Romeu & William A. Richards. (2018) Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30:4, pages 291-316.
Read now
Read now
Simon L. Hill & Simon H. L. Thomas. (2011) Clinical toxicology of newer recreational drugs. Clinical Toxicology 49:8, pages 705-719.
Read now
Read now
Articles from other publishers (60)
Adam Wojtas. (2023) The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacological Reports 75:6, pages 1313-1325.
Crossref
Crossref
Agnieszka Wsół. (2023) Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacological Reports 75:6, pages 1362-1380.
Crossref
Crossref
Andrew A. BolingerNoelle C. AnastasioKathryn A. CunninghamJia Zhou. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews
53
81
.
Christiane Martins de Vasconcellos Silveira, Vanessa Farelo dos Santos, Isis Moraes Ornelas, Beatriz de Sá Carrilho, Matheus Antonio Vieira de Castro Ventura, Henrique Marcelo Gualberto Pereira, Stevens Kastrup Rehen & Magno Junqueira. (2023) Systematic characterization of Lysergic Acid Diethylamide metabolites in Caenorhabditis elegans by ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry. Journal of Chromatography A 1708, pages 464362.
Crossref
Crossref
Rabeet Tariq. (2023) Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and
Potential Harms. Current Reviews in Clinical and Experimental Pharmacology 18:2, pages 94-109.
Crossref
Crossref
Gavin P. Schmitz & Bryan L. Roth. (2023) G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. American Journal of Physiology-Cell Physiology 325:1, pages C17-C28.
Crossref
Crossref
Oliver G. Bosch, Simon Halm & Erich Seifritz. (2022) Psychedelics in the treatment of unipolar and bipolar depression. International Journal of Bipolar Disorders 10:1.
Crossref
Crossref
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic, Lisa Mastin-Purcell & Greg Murray. (2022) The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. Systematic Reviews 11:1.
Crossref
Crossref
Ayse Ceren Kaypak & Amir Raz. (2022) Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives. Transcultural Psychiatry 59:5, pages 665-674.
Crossref
Crossref
Can Cao, Ximena Barros-Álvarez, Shicheng Zhang, Kuglae Kim, Marc A. Dämgen, Ouliana Panova, Carl-Mikael Suomivuori, Jonathan F. Fay, Xiaofang Zhong, Brian E. Krumm, Ryan H. Gumpper, Alpay B. Seven, Michael J. Robertson, Nevan J. Krogan, Ruth Hüttenhain, David E. Nichols, Ron O. Dror, Georgios Skiniotis & Bryan L. Roth. (2022) Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD. Neuron 110:19, pages 3154-3167.e7.
Crossref
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Crossref
Alaina M. Jaster, Mario de la Fuente Revenga & Javier González‐Maeso. (2021) Molecular targets of psychedelic‐induced plasticity. Journal of Neurochemistry 162:1, pages 80-88.
Crossref
Crossref
V. L. Matrenitsky. (2022) РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ. Likarska sprava:3-4, pages 37-59.
Crossref
Crossref
Tristan D. McClure-Begley & Bryan L. Roth. (2022) The promises and perils of psychedelic pharmacology for psychiatry. Nature Reviews Drug Discovery 21:6, pages 463-473.
Crossref
Crossref
Timothy Lawn, Ottavia Dipasquale, Alexandros Vamvakas, Ioannis Tsougos, Mitul A. Mehta & Matthew A. Howard. (2022) Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD. Psychopharmacology 239:6, pages 1797-1808.
Crossref
Crossref
Timothy Andrews & Katie Wright. (2022) The frontiers of new psychedelic therapies: A survey of sociological themes and issues. Sociology Compass 16:2.
Crossref
Crossref
Wm Maurice Redden, Saif-Ur-Rahman Paracha & Quratulanne Sheheryar. (2022) Hallucinogen Use and Misuse in Older Adults. Clinics in Geriatric Medicine 38:1, pages 55-66.
Crossref
Crossref
Kacper Lukasiewicz, Jacob J. Baker, Yi Zuo & Ju Lu. (2021) Serotonergic Psychedelics in Neural Plasticity. Frontiers in Molecular Neuroscience 14.
Crossref
Crossref
Johannes G Ramaekers, Nadia Hutten, Natasha L Mason, Patrick Dolder, Eef L Theunissen, Friederike Holze, Matthias E Liechti, Amanda Feilding & Kim PC Kuypers. (2020) A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of Psychopharmacology 35:4, pages 398-405.
Crossref
Crossref
Nicole L. Galvão-Coelho, Wolfgang Marx, Maria Gonzalez, Justin Sinclair, Michael de Manincor, Daniel Perkins & Jerome Sarris. (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology 238:2, pages 341-354.
Crossref
Crossref
Antonio Inserra, Danilo De Gregorio & Gabriella Gobbi. (2020) Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews 73:1, pages 202-277.
Crossref
Crossref
Inés Ibarra-Lecue, Rebeca Diez-Alarcia & Leyre Urigüen. 2021. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A
135
175
.
Fernanda Palhano-Fontes, Sérgio Mota-Rolim, Bruno Lobão-Soares, Nicole Galvão-Coelho, Joao Paulo Maia-Oliveira & Dráulio B. Araújo. 2021. Ayahuasca Healing and Science. Ayahuasca Healing and Science
21
41
.
Daniel Hoyer. (2020) Targeting the 5-HT system: Potential side effects. Neuropharmacology 179, pages 108233.
Crossref
Crossref
Rachel A. Caplan, Jonah P. Zuflacht, Jed A. Barash & Corey R. Fehnel. (2020) Neurotoxicology Syndromes Associated with Drugs of Abuse. Neurologic Clinics 38:4, pages 983-996.
Crossref
Crossref
Adam L. Halberstadt, Muhammad Chatha, Adam K. Klein, John D. McCorvy, Markus R. Meyer, Lea Wagmann, Alexander Stratford & Simon D. Brandt. (2020) Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD). Neuropharmacology 172, pages 107856.
Crossref
Crossref
Nurul Alyani Zainol Abidin, Faridah Kormin, Nurul Akhma Zainol Abidin, Nor Aini Fatihah Mohamed Anuar & Mohd Fadzelly Abu Bakar. (2020) The Potential of Insects as Alternative Sources of Chitin: An Overview on the Chemical Method of Extraction from Various Sources. International Journal of Molecular Sciences 21:14, pages 4978.
Crossref
Crossref
David J. Heal, Jack Henningfield, Bruno G. Frenguelli, David J. Nutt & Sharon L. Smith. (2018) Psychedelics – Re-opening the doors of perception. Neuropharmacology 142, pages 1-6.
Crossref
Crossref
Mark F. Bear, Barry W. Connors & Michael A. ParadisoMark F. Bear, Barry W. Connors & Michael A. Paradiso. 2018. Neurowissenschaften. Neurowissenschaften
559
589
.
José L. Moreno & Javier González-Maeso. 2018. 5-HT2A Receptors in the Central Nervous System. 5-HT2A Receptors in the Central Nervous System
147
189
.
Michael P. Bogenschutz & Alyssa A. Forcehimes. (2016) Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism. Journal of Humanistic Psychology 57:4, pages 389-414.
Crossref
Crossref
Qiuyan Chen & John J.G. Tesmer. (2017) A Receptor on Acid. Cell 168:3, pages 339-341.
Crossref
Crossref
Daniel Wacker, Sheng Wang, John D. McCorvy, Robin M. Betz, A.J. Venkatakrishnan, Anat Levit, Katherine Lansu, Zachary L. Schools, Tao Che, David E. Nichols, Brian K. Shoichet, Ron O. Dror & Bryan L. Roth. (2017) Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell 168:3, pages 377-389.e12.
Crossref
Crossref
Juan F. López-Giménez & Javier González-Maeso. 2018. Behavioral Neurobiology of Psychedelic Drugs. Behavioral Neurobiology of Psychedelic Drugs
45
73
.
Hermann A.M. Mucke. (2016) From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide. ASSAY and Drug Development Technologies 14:5, pages 276-281.
Crossref
Crossref
David E. Nichols. (2016) Psychedelics. Pharmacological Reviews 68:2, pages 264-355.
Crossref
Crossref
Monica F. Tomlinson, Matthew Brown & Peter N.S. Hoaken. (2016) Recreational drug use and human aggressive behavior: A comprehensive review since 2003. Aggression and Violent Behavior 27, pages 9-29.
Crossref
Crossref
Michael P. Bogenschutz & Matthew W. Johnson. (2016) Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 250-258.
Crossref
Crossref
Charles D. Nichols. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
859
865
.
Mitsumasa Kurita, Aintzane García-Bea & Javier González-Maeso. 2016. The Medical Basis of Psychiatry. The Medical Basis of Psychiatry
601
654
.
Michael P. Bogenschutz & Stephen Ross. 2018. Behavioral Neurobiology of Psychedelic Drugs. Behavioral Neurobiology of Psychedelic Drugs
361
391
.
Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H. Preller, Franz X. Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt & Matthias E. Liechti. (2015) Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biological Psychiatry 78:8, pages 544-553.
Crossref
Crossref
Daniel Hoyer. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
57
80
.
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie & Rudolf Brenneisen. (2014) Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. Journal of Nervous & Mental Disease 202:7, pages 513-520.
Crossref
Crossref
Ryan H.A. Chan & John E. Mendelson. 2014. The Effects of Drug Abuse on the Human Nervous System. The Effects of Drug Abuse on the Human Nervous System
533
552
.
Warunya Arunotayanun, Jeffrey W. Dalley, Xi-Ping Huang, Vincent Setola, Ric Treble, Leslie Iversen, Bryan L. Roth & Simon Gibbons. (2013) An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging ‘Novel Psychoactive Drugs’. Bioorganic & Medicinal Chemistry Letters 23:11, pages 3411-3415.
Crossref
Crossref
Fabiola Domínguez, Angel Alonso-Castro, Ma González-Trujano, Adrián Martínez-Cervantes, Hermelinda Salgado-Ceballos, Sergio Torres-Castillo & Sandra Orozco-Suárez. 2012. Medicinal Plants. Medicinal Plants
472
494
.
Louis A. Pagliaro & Ann Marie Pagliaro. 2011. Handbook of Child and Adolescent Drug and Substance Abuse. Handbook of Child and Adolescent Drug and Substance Abuse
371
453
.
Danuta Marona-Lewicka, Charles D. Nichols & David E. Nichols. (2011) An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology 61:3, pages 503-512.
Crossref
Crossref
Katherine M. Prevatt-Smith & Thomas E. Prisinzano. (2010) New therapeutic potential for psychoactive natural products. Nat. Prod. Rep. 27:1, pages 23-31.
Crossref
Crossref
. (2008) Psychedelic Medicine: New evidence for hallucinogenic substances and treatments. Volumes One and Two
Psychedelic Horizons. Journal of Psychiatric and Mental Health Nursing 15:9, pages 787-790.
Crossref
Crossref
A R Green. (2008) Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. British Journal of Pharmacology 154:8, pages 1583-1599.
Crossref
Crossref
Danuta Marona-Lewicka & David E. Nichols. (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacology Biochemistry and Behavior 87:4, pages 453-461.
Crossref
Crossref
M. Isabel Colado, Esther O'Shea & A. Richard Green. 2007. Handbook of Contemporary Neuropharmacology. Handbook of Contemporary Neuropharmacology.
Ben Sessa. (2016) Is there a case for MDMA-assisted psychotherapy in the UK?. Journal of Psychopharmacology 21:2, pages 220-224.
Crossref
Crossref
John C.M. Brust. 2007. Aspects neurologiques de l'addiction. Aspects neurologiques de l'addiction
315
334
.
Bryan L Roth, Estela Lopez, Scott Beischel, Richard B Westkaemper & Jon M Evans. (2004) Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacology & Therapeutics 102:2, pages 99-110.
Crossref
Crossref
David E Nichols. (2004) Hallucinogens. Pharmacology & Therapeutics 101:2, pages 131-181.
Crossref
Crossref
John C.M. Brust. 2004. Neurological Aspects of Substance Abuse. Neurological Aspects of Substance Abuse
259
274
.
Can Cao, Ximena Barros-Álvarez, Shicheng Zhang, Kuglae Kim, Marc A. Dämgen, Ouliana Panova, Carl-Mikael Suomivuori, Jonathan Fay, Xiaofang Zhong, Brian E. Krumm, Ryan H. Gumpper, Alpay B. Seven, Michael J. Robertson, Nevan J. Krogan, Ruth Hüttenhain, David E. Nichols, Ron O. Dror, Georgios Skiniotis & Bryan Roth. (2022) Signaling Snapshots of 5-HT <sub>2B</sub>R Activated by the Prototypical Psychedelic LSD. SSRN Electronic Journal.
Crossref
Crossref